Pancreatic Testing: A Composite Diagnosis, Not a Number

Quick Answer — Pancreatic lipase immunoreactivity is the best single laboratory test for pancreatitis, and it is still not a diagnosis. The disease is defined by a combination of compatible clinical signs, an elevated pancreas-specific lipase, and supporting imaging or laboratory evidence. Everything that goes wrong with this test goes wrong at the boundary between “elevated” and “diagnosed”.

Quick Answer

The test measures enzyme leakage, not disease severity. Use it to support a composite, not to replace one.

What the assay adds

Comparison	Catalytic lipase activity	Pancreatic lipase immunoreactivity
Specificity for pancreas	Low — multiple sources	High — pancreatic protein
Affected by renal clearance	Yes	Less so
Use in cats	Particularly unreliable	Preferred
Interpretation	Poorly standardised across labs	Assay-specific thresholds

The move from activity to immunoreactivity is the single biggest improvement in this area, and it is why the test deserves its own page rather than a paragraph on a general chemistry panel.

Where it changes management

1. Confirming a clinical suspicion in a dog with vomiting, cranial abdominal pain and an equivocal ultrasound.
2. Resolving discordance — a high value with a normal pancreas, or a normal value with an abnormal one, both teach something.
3. Supporting a decision to treat intensively rather than send home, when signs are mild but the value is markedly elevated.
4. Feline cases, where clinical signs are often non-specific and imaging can be inconclusive.

Where it does not

• Severity assessment. The magnitude does not reliably predict outcome; organ dysfunction and clinical status do.
• Excluding disease. Mild, chronic and focal pancreatitis can sit inside the interval.
• Stand-alone diagnosis. Especially in cats, and especially with concurrent disease.
• Rapid monitoring. Values lag clinical improvement by days.

The feline complication

In cats, pancreatitis is commonly part of a triad with cholangitis and inflammatory bowel disease. A modestly elevated fPL in that setting may reflect shared inflammation rather than a primary pancreatic event, and treating it as primary pancreatitis leads to an incomplete plan.

The useful pairing is fPL with an acute-phase protein:

fPL	SAA	Reading
High	High	Pancreatitis with systemic response
High	Normal	Pancreatic involvement, no systemic response
Normal	High	Inflammation elsewhere — biliary, intestinal, urinary

Data pending. This section reports measured values from internal validation studies. They are published once the supporting study is complete; the current report is available from technical support on request.

Thresholds, and why portability matters

Data pending. This section reports measured values from internal validation studies. They are published once the supporting study is complete; the current report is available from technical support on request.

This warning belongs in the body of the page, not a footnote: clinics switching platforms commonly carry their old thresholds with them, and the resulting misclassification is silent.

Six traps

1. Diagnosing on a single elevated value. The composite is the diagnosis.
2. Excluding pancreatitis on a normal value. Chronic and focal forms exist.
3. Using the number as a severity score. Clinical status decides severity.
4. Importing thresholds. Systematic misclassification.
5. Expecting rapid normalisation. Values lag improvement.
6. Ignoring concurrent disease in cats. Triaditis changes the plan.

The Author’s Take

Position. The commercially useful promise is not “detects pancreatitis” but “resolves the case where you are unsure” — and that promise is kept by publishing a decision table, not by claiming sensitivity.

Reasoning. Every vendor claims detection. What clinicians cannot buy anywhere is help with the ambiguous case: the mildly elevated value in a well-looking dog, the normal value in a cat that clearly has something wrong. Those cases consume clinical time and generate repeat visits, and a decision table shortens them at zero experimental cost. It also has a defensive function: the most common complaint about a pancreatic assay is that it “was wrong” in a case where the interpretation, not the assay, was the problem. Publishing the table pre-empts that complaint by making the interpretation the clinic’s stated protocol.

Disclosure. Written from published veterinary pancreatitis literature; no new experimental data. Values marked are placeholders for Migibio’s platform data.

Related pages

• Canine pancreatitis · Feline pancreatitis
• Canine pancreatic lipase · Feline pancreatic lipase · Feline SAA
• Reference intervals

Sources

1. Reference to be added.
2. Reference to be added.
3. CLSI EP28-A3c — reference interval versus decision limit methodology.